Impax Laboratories Strengthens Leadership by Adding New Senior Vice Presidents for Global Operations and Global Quality Affairs
June 21 2011 - 11:30AM
Business Wire
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced
two executive appointments that will strengthen the company’s
leadership in the critical areas of operations and quality affairs.
The company has appointed Mark Fitch as Senior Vice President
Global Operations and Jeff Nornhold as Senior Vice President Global
Quality Affairs. Both Mr. Fitch and Mr. Nornhold will report to
Impax’s President and Chief Executive Officer, Larry Hsu, Ph.D.
Mr. Fitch brings over 35 years of pharmaceutical experience to
his role at Impax. He joins the company from Nycomed US, where he
was Senior Vice President Operations. Prior to joining Nycomed, he
was a consultant in the pharmaceutical industry, and before that he
spent 10 years with Mylan Pharmaceuticals as a member of the
executive team that led Mylan through its critical growth period,
including key acquisitions. During his tenure with Mylan, he was
responsible for all manufacturing plant operations, facilities
engineering, maintenance, safety, security and technical support at
solid dosage form plants in West Virginia and Puerto Rico. He
earned his Bachelor of Science degree in pharmacy and
pharmaceutical sciences at Purdue University.
Mr. Nornhold, who has 20 years of pharmaceutical industry
experience, joins Impax from Watson Pharmaceuticals, Inc., where he
was most recently Vice President, Quality Operations –
International, and was responsible for outside of the U.S.
manufacturing sites for both dosage and active pharmaceutical
ingredients. While at Watson, he also served as Vice President U.S.
Quality Operations leading the development and execution of quality
initiatives for all U.S. sites. Prior to joining Watson in 2000, he
held numerous leadership positions within the pharmaceuticals
industry. He earned a Bachelor of Science degree in chemistry from
Bowling Green State University and a Master’s in Business
Administration from the University of Southern California Marshall
School of Business.
“We are very pleased that Mark and Jeff have joined Impax to
oversee these two very critical areas of our business,” said Larry
Hsu, Ph.D., president and CEO of Impax. “They are accomplished
executives with a strong track record and extensive pharmaceutical
and business leadership experience. We have experienced significant
growth the past several years and their addition further enhances
our management team.”
About Impax Laboratories, Inc.
Impax Laboratories, Inc. (“Impax”) is a technology based
specialty pharmaceutical company applying its formulation expertise
and drug delivery technology to the development of
controlled-release and specialty generics in addition to the
development of branded products. Impax markets its generic products
through its Global Pharmaceuticals division and markets its branded
products through the Impax Pharmaceuticals division. Additionally,
where strategically appropriate, Impax has developed marketing
partnerships to fully leverage its technology platform. Impax is
headquartered in Hayward, California, and has a full range of
capabilities in its Hayward, Philadelphia and Taiwan facilities.
For more information, please visit the Company's Website at:
www.impaxlabs.com.
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jul 2024 to Jul 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jul 2023 to Jul 2024